scholarly journals Dietary intake and body composition in HIV-positive and -negative South African women

2013 ◽  
Vol 17 (7) ◽  
pp. 1603-1613 ◽  
Author(s):  
Stephanie V Wrottesley ◽  
Lisa K Micklesfield ◽  
Matthew M Hamill ◽  
Gail R Goldberg ◽  
Ann Prentice ◽  
...  

AbstractObjectiveThe present paper examines dietary intake and body composition in antiretroviral (ARV)-naïve HIV-positive compared with HIV-negative South African women, as well as the impact of disease severity on these variables.DesignBaseline data from a longitudinal study assessing bone health in HIV-negative and HIV-positive premenopausal South African women over 18 years of age were used. Anthropometry and body composition, measured by dual energy X-ray absorptiometry, were analysed together with dietary intake data assessed using an interviewer-based quantitative FFQ.SettingSoweto, Johannesburg, South Africa.SubjectsBlack, urban South African women were divided into three groups: (i) HIV-negative (HIV−; n 98); (ii) HIV-positive with preserved CD4 counts (HIV+ non-ARV; n 74); and (iii) HIV-positive with low CD4 counts and due to start ARV treatment (HIV+ pre-ARV; n 75).ResultsThe prevalence of overweight and obesity was high in this population (59 %). The HIV+ pre-ARV group was lighter and had a lower BMI than the other two groups (all P < 0·001). HIV+ pre-ARV women also had lower fat and lean masses and percentage body fat than their HIV− and HIV+ non-ARV counterparts. After adjustment, there were no differences in macronutrient intakes across study groups; however, fat and sugar intakes were high and consumption of predominantly refined food items was common overall.ConclusionHIV-associated immunosuppression may be a key determinant of body composition in HIV-positive women. However, in populations with high obesity prevalence, these differences become evident only at advanced stages of infection.

2011 ◽  
Vol 51 (6) ◽  
pp. 546-565 ◽  
Author(s):  
Jonathan P. Mundell ◽  
Maretha J. Visser ◽  
Jennifer D. Makin ◽  
Trace S. Kershaw ◽  
Brian W. C. Forsyth ◽  
...  

Viruses ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 280
Author(s):  
Ongeziwe Taku ◽  
Zizipho Z. A. Mbulawa ◽  
Keletso Phohlo ◽  
Mirta Garcia-Jardon ◽  
Charles B. Businge ◽  
...  

South African women have a high rate of cervical cancer cases, but there are limited data on human papillomavirus (HPV) genotypes in cervical intraepithelial neoplasia (CIN) in the Eastern Cape province, South Africa. A total of 193 cervical specimens with confirmed CIN from women aged 18 years or older, recruited from a referral hospital, were tested for HPV infection. The cervical specimens, smeared onto FTA cards, were screened for 36 HPV types using an HPV direct flow kit. HPV prevalence was 93.5% (43/46) in CIN2 and 96.6% (142/147) in CIN3. HIV-positive women had a significantly higher HPV prevalence than HIV-negative women (98.0% vs. 89.1%, p = 0.012). The prevalence of multiple types was significantly higher in HIV-positive than HIV-negative women (p = 0.034). The frequently detected genotypes were HPV35 (23.9%), HPV58 (23.9%), HPV45 (19.6%), and HPV16 (17.3%) in CIN2 cases, while in CIN3, HPV35 (22.5%), HPV16 (21.8%), HPV33 (15.6%), and HPV58 (14.3%) were the most common identified HPV types, independent of HIV status. The prevalence of HPV types targeted by the nonavalent HPV vaccine was 60.9% and 68.7% among women with CIN2 and CIN3, respectively, indicating that vaccination would have an impact both in HIV-negative and HIV-positive South African women, although it will not provide full protection in preventing HPV infection and cervical cancer lesions.


2012 ◽  
Vol 15 (10) ◽  
pp. 1810-1817 ◽  
Author(s):  
Peggy C Papathakis ◽  
Kerry E Pearson

AbstractObjectiveTo investigate the impact of fortification by comparing food records and selected biochemical indicators of nutritional status pre- and post-fortification.DesignMean intake from 24 h recalls (n 142) was compared with the Estimated Average Requirement (EAR) to determine the proportion with inadequate intake. In a subsample (n 34), diet and serum retinol, folate, ferritin and Zn were compared pre- and post-fortification for fortified nutrients vitamin A, thiamin, riboflavin, niacin, folic acid, Fe and Zn.SettingSouth Africa.SubjectsBreast-feeding women (ninety-four HIV-infected, forty eight HIV-uninfected) measured at ∼6, 14, 24 weeks, and 9 and 12 months postpartum.ResultsPre-fortification, >80 % of women did not meet the EAR for vitamins A, C, D, thiamin, riboflavin, niacin, B6, B12 and folate and minerals Zn, iodine and Ca. Dietary intake post-fortification increased for all fortified nutrients. In post-fortification food records, >70 % did not meet the EAR for Zn and vitamins A, riboflavin and B6. Serum folate and Zn increased significantly post-fortification (P < 0·001 for both), with no change in ferritin and a reduction in retinol. Post-fortification marginal/deficient folate status was reduced (73·5 % pre v. 3·0 % post; P < 0·001), as was Zn deficiency (26·5 % pre v. 5·9 % post; P < 0·05). Pre- and post-fortification, >93 % were retinol replete. There was no change in Fe deficiency (16·7 % pre v. 19·4 % post; P = 0·728).ConclusionsMicronutrient intake improved with fortification, but >70 % of lactating women did not meet the EAR for Zn, vitamins A, riboflavin and B6. Although 100 % exceeded the EAR for Fe after fortification, Fe status did not improve.


PLoS ONE ◽  
2015 ◽  
Vol 10 (7) ◽  
pp. e0132914 ◽  
Author(s):  
Philippe Jean-Luc Gradidge ◽  
Shane A. Norris ◽  
Lisa K. Micklesfield ◽  
Nigel J. Crowther

2011 ◽  
Vol 10 (3) ◽  
pp. 248-264 ◽  
Author(s):  
Dorina Onoya ◽  
Priscilla Reddy ◽  
Sibusiso Sifunda ◽  
Gina M. Wingood ◽  
Bart van den Borne ◽  
...  

2017 ◽  
Vol 94 (1) ◽  
pp. 55-61 ◽  
Author(s):  
Lynette J Menezes ◽  
Ubin Pokharel ◽  
Staci L Sudenga ◽  
Matthys H Botha ◽  
Michele Zeier ◽  
...  

ObjectiveTo estimate the prevalence and describe the patterns of concurrent human papillomavirus (HPV) and STIs and associated factors among HIV-negative young Western Cape, South African women participating in the Efficacy of HPV Vaccine to Reduce HIV Infection (EVRI) trial.MethodsHIV-negative women aged 16–24 years old were enrolled in the EVRI trial (NCT01489527) and randomised to receive the licensed four-valent HPV vaccine or placebo. At study entry, participants were clinically evaluated for five STIs: herpes simplex virus type 2 (HSV-2), chlamydia, gonorrhoea, syphilis and disease-causing HPV genotypes (6/11/16/18/31/33/35/39/45/51/52/56/58/59/68). Demographic and sexual history characteristics were compared among women with STI co-infections, single infection and no infection using Pearson χ2 and Mann-Whitney tests. ORs were calculated to evaluate factors associated with STI co-infection prevalence.ResultsAmong 388 young women, STI co-infection prevalence was high: 47% had ≥2 concurrent STIs, 36% had a single STI and 17% had none of the five evaluated STIs. HPV/HSV-2 (26%) was the most prevalent co-infection detected followed by HPV/HSV-2/Chlamydia trachomatis (CT) (17%) and HPV/CT (15%). Co-infection prevalence was independently associated with alcohol use (adjusted OR=2.01, 95% CI 1.00 to 4.06) and having a sexual partner with an STI (adjusted OR=6.96, 95% CI 1.53 to 30.08).ConclusionsAmong high-risk young women from underserved communities such as in Southern Africa, a multicomponent prevention strategy that integrates medical and behavioural interventions targeting both men and women is essential to prevent acquisition of concurrent STI infections and consequent disease.Trial registration numberNCT01489527; Post-results.


PLoS ONE ◽  
2020 ◽  
Vol 15 (6) ◽  
pp. e0235162
Author(s):  
Charlene Akoto ◽  
Christina Y. S. Chan ◽  
Krithi Ravi ◽  
Wei Zhang ◽  
Manu Vatish ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document